Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPhase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer
Cancer Chemotherapy and Pharmacology, 06/30/09
Park I et al. - The pharmacokinetics of S-1 was not influenced by oxaliplatin. S-1/Oxaliplatin combination therapy is highly active against AGC and has a favorable toxicity profile.
Related Articles
CHD5 is down-regulated through promoter hypermethylation in gastric cancer
BMC: Journal of Biomedical Science, 10/26/09
Relevance Score: 71%
Promoter hypermethylation mediates downregulation of thiamine receptor slc19a3 in gastric cancer
Tumor Biology, 10/12/09
Relevance Score: 71%
KAP1 Is Associated With Peritoneal Carcinomatosis in Gastric Cancer
Annals of Surgical Oncology, 11/11/09
Relevance Score: 69%
Management of patients with pregnancy-associated gastric cancer in Japan: a mini-review
International Journal of Clinical Oncology, 10/30/09
Relevance Score: 69%
A Study of Oxidative Stress Parameters in Anti-Helicobacter Pylorus Immunoglobulin G Positive and Negative Gastric Cancer Patients
Yonsei Medical Journal, 10/29/09
Relevance Score: 69%
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma
Journal of Cancer Research & Clinical Oncology, 11/24/09
Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-mTOR pathway
Journal of Clinical Oncology, 11/24/09
XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk
BMC Cancer, 11/20/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor